Aurobindo Pharma Fact Sheet, Aurobindo Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Fact Sheet    (AUBD)


New: A Potential 10x Opportunity in the Long Term


Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

AUROBINDO PHARMA Price History

Price Rs 853.6
Mkt Cap Rs m 499,500
Vol '000 186.6
P/E X 16.6
P/CF X 16.5
EPS (TTM) Rs 51.4
% ch % -3.0
No. of shares m 585.17
% ch week % -0.2
% ch 1-mth % 9.0
% ch 12-mth % 93.8
52 week H/L Rs 967.6/281.2
(As on Nov 25, 2020 03:34:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AUROBINDO PHARMA Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
5-Yr Chart
Click to enlarge
AUROBINDO PHARMA EQUITY SHARE DATA
High Rs1,2801,541895809830 
Low Rs509582622504527 
Sales per share (Unadj.) Rs415.1235.8254.6281.6333.9 
Earnings per share (Unadj.) Rs54.034.639.341.440.4 
Diluted earnings per shareRs26.934.639.341.440.4 
Cash flow per share (Unadj.) Rs65.441.346.650.951.8 
Dividends per share (Unadj.) Rs4.502.502.502.502.50 
Adj. dividends per shareRs2.252.502.502.502.50 
Dividend yield (eoy) %0.50.20.30.40.4 
Book value per share (Unadj.) Rs184.5124.5160.0199.4237.1 
Adj. book value per shareRs92.0124.5160.2199.6237.4 
Shares outstanding (eoy) m291.98585.17585.88585.88585.91 
Bonus/Rights/Conversions  -PREFESOP-ESOP 
Price / Sales ratio x2.24.53.02.32.0 
Avg P/E ratio x16.630.719.315.916.8 
P/CF ratio (eoy) x13.725.716.312.913.1 
Price / Book Value ratio x4.88.54.73.32.9 
Dividend payout %8.37.26.46.06.2 
Avg Mkt Cap Rs m261,147621,041444,390384,630397,569 
No. of employees `00011.613.314.017.317.9 
Total wages/salary Rs m13,02315,42617,67821,30825,849 
Avg. sales/employee Rs Th10,469.510,384.310,667.89,519.910,956.9 
Avg. wages/employee Rs Th1,124.91,160.91,264.31,229.41,447.7 
Avg. net profit/employee Rs Th1,361.11,522.91,645.81,397.91,324.3 
AUROBINDO PHARMA INCOME DATA
Net Sales Rs m121,205137,986149,157164,998195,636 
Other income Rs m9672,0381,1591,0201,553 
Total revenues Rs m122,172140,024150,316166,018197,189 
Gross profit Rs m25,63631,88234,34337,71839,519 
Depreciation Rs m3,3263,9244,2765,5806,680 
Interest Rs m1,5992,5686677772,626 
Profit before tax Rs m21,67927,42930,55832,38031,767 
Minority Interest Rs m4515503127 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000-881 
Tax Rs m5,9667,2077,5978,1837,269 
Profit after tax Rs m15,75820,23623,01224,22923,645 
Gross profit margin %21.223.123.022.920.2 
Effective tax rate %27.526.324.925.322.9 
Net profit margin %13.014.715.414.712.1 
AUROBINDO PHARMA BALANCE SHEET DATA
Current assets Rs m83,794102,94492,062121,878153,645 
Current liabilities Rs m60,81478,40266,05686,659120,429 
Net working cap to sales %19.017.817.421.317.0 
Current ratio x1.41.31.41.41.3 
Inventory Days Days108107106130135 
Debtors Days Days107122686864 
Net fixed assets Rs m39,21850,27862,91983,345103,909 
Share capital Rs m292585586586586 
"Free" reserves Rs m53,56572,28893,133116,218138,322 
Net worth Rs m53,85772,87393,719116,804138,908 
Long term debt Rs m13,1117,4281,8144,5121,800 
Total assets Rs m128,124159,202162,494211,052264,544 
Interest coverage x14.611.746.842.713.1 
Debt to equity ratio x0.20.1000 
Sales to assets ratio x0.90.90.90.80.7 
Return on assets %13.514.314.611.89.9 
Return on equity %29.327.824.620.717.0 
Return on capital %34.837.432.727.423.8 
Exports to sales %51.651.450.848.949.6 
Imports to sales %19.219.018.219.318.8 
Exports (fob) Rs m62,51470,92775,76180,68197,091 
Imports (cif) Rs m23,27226,19327,08931,85336,741 
Fx inflow Rs m62,61371,01575,83880,72797,316 
Fx outflow Rs m25,32928,79930,22434,70040,589 
Net fx Rs m37,28442,21645,61346,02756,727 
AUROBINDO PHARMA CASH FLOW
From Operations Rs m 12,368 14,198 32,786 19,545 16,220 
From Investments Rs m -13,980 -14,452 -17,870 -19,266 -28,768 
From Financial Activity Rs m 932 3,654 -19,153 8,642 19,191 
Net Cashflow Rs m -680 3,397 -4,239 8,919 6,656 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 54.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 8.0%
FIIs 27.7%
ADR/GDR 0.0%
Free float 10.2%
Shareholders 69,601
Pledged promoter(s) holding 8.6%
 

Company Information

REGD OFF Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038
E-MAIL cs@aurobindo.com WEB www.aurobindo.com
TELEPHONE (040) 6672 5333 FAX (040) 2374 1080
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR S. R. Batliboi & Assoc.
CHM: K. Ragunathan COMP SEC: A. Mohan Rami Reddy YEAR OF INC: 1986 BSE CODE: 524804 FV (Rs): 1 DIV YIELD (%): 0.3

Read: AUROBINDO PHARMA 2018-19 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   TORRENT PHARMA  SHASUN PHARMA  NATCO PHARMA  WOCKHARDT  PROCTER & GAMBLE HEALTH  

Compare AUROBINDO PHARMA With:   TORRENT PHARMA  SHASUN PHARMA  NATCO PHARMA  WOCKHARDT  PROCTER & GAMBLE HEALTH  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  




Today's Market

Sensex Corrects Over 600 Points; Private Bank & IT Stocks Under Pressure(02:30 pm)

Share markets in India have extended losses and are presently trading deep in the red, dragged down by financials and IT stocks.

Views on news

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

This Diwali Consider Richa's #1 Stock Pick for 2021 (Profit Hunter)

Nov 13, 2020

Why I admire the approach that Richa uses to zero in on stocks with huge upside potential.

Don't Let Brokerages Fool You into Buying HUL & Nestle. The Real Money is in These Stocks Right Now... Views On News (Views On News)

Nov 12, 2020

Rahul Shah discusses why he preferred a little known stock over Nestle Ltd and how he was proven right.

How to Short Sell the Right Way (Fast Profits Daily)

Nov 13, 2020

In this video, I'll show you how to short sell effectively.

Stocks that Could Shine More than Gold After Diwali (Profit Hunter)

Nov 17, 2020

If the markets become volatile over the next few months, do this.

US Elections: Won a Battle, Now the War (The Honest Truth)

Nov 13, 2020

Ajit Dayal on the urgent need to fix the disparity between the rich and the poor in the US.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - MYLAN COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS